Special Issue "The Role of Stereotactic Ablative Radiotherapy in the Management of Localized and Metastatic Genitourinary Tumours"
Deadline for manuscript submissions: 29 February 2024 | Viewed by 225
Interests: urological malignancies; radiation oncology; new fractionation protocols; treatment accuracy; patient’s quality of life; prognostic and predictive factors; SBRT hypofractionation; oligometastatic disease
Special Issues, Collections and Topics in MDPI journals
The development of stereotactic body radiotherapy (SBRT), building on its intrinsic physical properties, restriction of tumour movement during treatment (tumour motion management) and meticulous verification of tumour position before and during treatment (image-guided radiation therapy (IGRT)), now allows for the delivery of ablative doses of radiation to both primary and metastatic tumours with high control rates and minimal toxicity.
Accumulating evidence shows that SBRT is an attractive approach to reduce the burden of care without losing clinical effectiveness, and is entitled to become the procedure of choice for the management of many patients with primary and/or oligometastatic GU malignancies, especially in light of the increasing number of elderly patients in need of treatment. Furthermore, the success of SBRT, relying on its ability to deliver high radiation doses to the target and yet sparing the surrounding normal tissues, seems to be confirmed in radioresistant histologies (i.e., renal tumours, sarcomas), thus defying the principles of the established radiobiological paradigm. An in-depth analysis of several aspects underlying the role of SBRT in this setting, as well as its potential interaction with the newest systemic therapies, will aid in the development of new therapeutic strategies in these common and often undertreated diseases.
Dr. Stefano Arcangeli
Dr. Giulia Marvaso
Dr. Denis Panizza
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- stereotactic body radiation therapy (SBRT)
- image-guided radiation therapy (IGRT)
- prostate cancer
- kidney cancer
- motion management
- androgen deprivation therapy (ADT)
- targeted therapy